(CercleFinance.com) – While maintaining its ‘neutral’ opinion on bioMérieux, Oddo BHF raises its price target from 105 to 113 euros, the day after the presentation of a medium-term roadmap which ‘would rather be at – above or at the high end of consensus expectations’.
‘We found the company rather confident and explicit, in short rather convincing, on its growth levers and efficiency measures’, judges the analyst, who also notes ‘a surprisingly voluntary message on M&A’.
Ultimately, Oddo BHF believes that bioMérieux ‘offers a medium-term plan and visibility, and addresses issues that the market was waiting for, presents a solid trajectory and manages to demonstrate that the effects of scale will finally become material’.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
